Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation
- PMID: 2014965
- PMCID: PMC244950
- DOI: 10.1128/AAC.35.1.111
Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation
Abstract
Aminoglycosides are usually considered to be concentration-dependent antibiotics and to have similar pharmacodynamic and pharmacokinetic properties. To verify the equivalent activity of the aminoglycosides on a susceptible strain, we tested the killing rate of three aminoglycosides (gentamicin, tobramycin, and amikacin) on one strain of Serratia marcescens both in vitro and in vivo by using a rabbit model of left-ventricle endocarditis. Despite, similar MICs, the time-kill curve of gentamicin was consistently better than those of amikacin and tobramycin, whatever the concentration of each antibiotic used (1, 2, 4, 8, 16, or 32 mg/liter), after a 5-h incubation. The in vivo bacterial reduction in the vegetations was measured 24 h after administration of an intravenous 48-mg/kg bolus of each antibiotic or at the end of a 24-h continuous intravenous infusion of the same dose. Gentamicin was significantly more effective when administered as a bolus than when administered as a continuous infusion (2.8 +/- 0.2 versus 6.4 +/- 1.5 log10 CFU/g of vegetation, respectively; P less than 0.01), whereas amikacin was more effective as a continuous infusion than as a bolus injection (3.6 +/- 2.0 versus 7.5 +/- 1.3 log10 CFU/g of vegetation, respectively; P less than 0.01). Tobramycin was not very effective, whatever the dosage tested (approximately 6.5 to 7 log10 CFU/g). These results suggest that concentration-dependent bactericidal activities, both in vitro and in vivo, may vary greatly among aminoglycosides despite similar MICs.
Similar articles
-
Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditis.Antimicrob Agents Chemother. 1992 Apr;36(4):744-50. doi: 10.1128/AAC.36.4.744. Antimicrob Agents Chemother. 1992. PMID: 1503436 Free PMC article.
-
Gentamicin-resistant Serratia marcescens endophthalmitis.Arch Ophthalmol. 1980 Jul;98(7):1221-3. doi: 10.1001/archopht.1980.01020040073007. Arch Ophthalmol. 1980. PMID: 6994702
-
[Comparison of the bactericidal activity of three aminosides: gentamicin, tobramycin and amikacin].Pathol Biol (Paris). 1987 May;35(5):461-5. Pathol Biol (Paris). 1987. PMID: 3302848 French.
-
Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.Expert Rev Anti Infect Ther. 2017 Jun;15(6):519-526. doi: 10.1080/14787210.2017.1316193. Epub 2017 Apr 17. Expert Rev Anti Infect Ther. 2017. PMID: 28375030 Review.
-
Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions.Am J Med. 1986 Jun 30;80(6B):126-37. doi: 10.1016/0002-9343(86)90490-0. Am J Med. 1986. PMID: 3088998 Review.
Cited by
-
Identification of factors affecting in vivo aminoglycoside activity in an experimental model of gram-negative endocarditis.Antimicrob Agents Chemother. 1992 Apr;36(4):744-50. doi: 10.1128/AAC.36.4.744. Antimicrob Agents Chemother. 1992. PMID: 1503436 Free PMC article.
-
What is the evidence for once-daily aminoglycoside therapy?Clin Pharmacokinet. 1994 Jul;27(1):32-48. doi: 10.2165/00003088-199427010-00004. Clin Pharmacokinet. 1994. PMID: 7955770 Review.
-
Fusogenic porous silicon nanoparticles as a broad-spectrum immunotherapy against bacterial infections.Nanoscale Horiz. 2021 Apr 1;6(4):330-340. doi: 10.1039/d0nh00624f. Epub 2021 Feb 18. Nanoscale Horiz. 2021. PMID: 33599221 Free PMC article.
-
A pharmacodynamic model for the action of the antibiotic imipenem on Pseudomonas aeruginosa populations in vitro.Bull Math Biol. 1996 Sep;58(5):923-38. doi: 10.1007/BF02459490. Bull Math Biol. 1996. PMID: 8837524
-
Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa.Antimicrob Agents Chemother. 1996 Apr;40(4):904-8. doi: 10.1128/AAC.40.4.904. Antimicrob Agents Chemother. 1996. PMID: 8849249 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources